<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721665</url>
  </required_header>
  <id_info>
    <org_study_id>NAFLD_01</org_study_id>
    <nct_id>NCT04721665</nct_id>
  </id_info>
  <brief_title>German NAFLD-Registry (Deutsches NAFLD-Register)</brief_title>
  <official_title>German NAFLD-Registry Characterization of Patients With Non-alcoholic Fatty Liver Disease (NAFLD) in Germany - Phase 1 (Observation of the Natural Course)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leberstiftungs-GmbH Deutschland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leberstiftungs-GmbH Deutschland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Characterization of patients with non-alcoholic fatty liver disease (NAFLD)&#xD;
&#xD;
      The German NAFLD-Registry (Deutsches NAFLD-Register) a project of the German Liver Foundation&#xD;
      (Deutsche Leberstiftung), managed by Leberstiftungs-GmbH Deutschland.&#xD;
&#xD;
      The German NAFLD-Registry is financially supported by Gilead Sciences GmbH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following data can be documented:&#xD;
&#xD;
        -  physical examination and vital parameters (e.g. age, weight)&#xD;
&#xD;
        -  comorbidities (e.g. diabetes mellitus, cardiovascular disease)&#xD;
&#xD;
        -  comedication (treatment of comorbidities related to NAFLD)&#xD;
&#xD;
        -  laboratory values (e.g. liver function tests, creatinine)&#xD;
&#xD;
        -  genetic variants (e.g. PNPLA3)&#xD;
&#xD;
        -  liver diagnostics (e.g. histological findings, sonographic findings)&#xD;
&#xD;
        -  lifestyle (alcohol consumption, physical activity)&#xD;
&#xD;
        -  health related quality of life (SF-36 questionnaire)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2036</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>Progression of liver fibrosis</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Fibrosis stage is measured by elastography (elastometry kPa value).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of nonalcoholic steatohepatitis (NASH)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Activity is measured via histology (NAFLD activity score represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The onset of the clinical outcome cardiovascular events (yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor diseases</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The onset of the clinical outcome tumor diseases (yes/no)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>NAFLD patients</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The number of patients to be enrolled with NAFL (bland steatosis) and NAFLD (without&#xD;
        histological diagnosis) and normal liver stiffness (Fibroscan® &lt;7.0 kPa) is limited to&#xD;
        1,000.&#xD;
&#xD;
        At least 1,000 of the 5,000 documented patients should have a histological diagnosis of the&#xD;
        disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed NAFLD based on the following criteria:&#xD;
&#xD;
               1. typical finding of hepatic steatosis (abdominal ultrasound and/or pathological&#xD;
                  CAP value (latter is optional)&#xD;
&#xD;
               2. Evaluation of NAFLD degree by NAFLD Fibrosis score and/or FIB-4-Index and/or&#xD;
                  transient elastography&#xD;
&#xD;
               3. Evaluation of metabolic syndrome&#xD;
&#xD;
          -  alcohol consumption &lt;20 g/day (women) and &lt;30 g/day (men)&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with other hepatologic diseases (chronically viral, metabolic, autoimmune&#xD;
             origin&#xD;
&#xD;
          -  patients receiving hepatotoxic medications over a longer period (e.g. methotrexate,&#xD;
             amiodarone, longterm NSAR intake)&#xD;
&#xD;
          -  relevant alcoholic liver disease [alcohol consumption &gt;20 g/day (women), &gt;30 g/day&#xD;
             (men)]&#xD;
&#xD;
          -  malignant disease with a life expectancy &lt;12 months&#xD;
&#xD;
          -  participation in clinical interventional/pivotal studies&#xD;
&#xD;
          -  inability to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zeuzem, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvonne Serfert, Dr.</last_name>
    <phone>+49511532</phone>
    <phone_ext>6968</phone_ext>
    <email>info@leberstiftungs-gmbh.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infektiologisches Zentrum Steglitz</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon Weinberg, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leber- und Studienzentrum Checkpoint</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renate Heyne, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ für Gastroenterologie am Bayerischen Platz</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolf P Hofmann, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin mit Schwerpunkt Gastroenterologie Dr. med. Jeannette Schwenzer</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannette Schwenzer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Ludwig und Dikopoulos</name>
      <address>
        <city>Dornstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nektarios Dikopoulos, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fachinternistische Schwerpunktpraxis</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Kahl, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Studiengesellschaft Herne</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred von der Ohe, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leberstudienzentrum Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hinrichsen, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Viszeralmedizin GmbH</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Schmidt, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eugastro GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingolf Schiefke, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Dres. Eisenbach,Simon, Schwarz GbR</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Georg Simon, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Kerstin Stein</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Stein, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIM GmbH</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Christensen, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Hospital Medizinische Klinik II</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Sarrazin, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.deutsches-nafld-register.de/</url>
    <description>Related information on the registry</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

